David Bautz
Research analyst, biotech, small-cap, medium-term horizon

AmpliPhi Biosciences: Developer Of Antibacterial 'Smartbombs'

AmpliPhi Biosciences (OTC: APHB) is a biopharmaceutical company focused on the discovery, development and commercialization of bacteriophage treatments for bacterial infections. Bacteriophages are viruses that infect, replicate in, and kill bacterial cells while not harming eukaryotic cells. This exclusivity is vital to their use in combating infectious diseases, and their unique mechanism of action compared to traditional antibiotics means they can be used in place of or in conjunction with those therapies. In addition, with the rise of antibiotic resistant bacteria, there is a pressing need for more and better treatments for bacterial infections that are resistant to the effects of antibiotics.

AmpliPhi has three lead compounds currently under development: AmpliPhage-001 is being developed for the treatment of Pseudomonas

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details